SEC CHARGES KIROMIC BIOPHARMA AND TWO FORMER C-SUITE EXECUTIVES WITH MISLEADING INVESTORS ABOUT STATUS OF FDA REVIEWS

The Securities and Exchange Commission filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma, Inc...

You need to be a subscriber to view this article. It's free!

Sign In / Sign Up

SEC Failure to Disclose misleading information

CN Editor

December 04, 2024

Click here to view source article

Related Articles

CIRO SANCTIONS FORMER INVESTORS GROUP REP FROM WINNIPEG, MANITOBA

November 29, 2024

FCA FINES FORMER AIRLINE EXECUTIVE FOR TRADING DURING CLOSED PERIODS AND FOR TRADE DISCLOSURE FAILURES

November 28, 2024

SEC UPDATES LIST OF FIRMS USING INACCURATE INFORMATION TO SOLICIT INVESTORS

November 28, 2024

SEC CHARGES KEN LEECH, FORMER CO-CHIEF INVESTMENT OFFICER OF WESTERN ASSET MANAGEMENT CO., WITH FRAUD

November 28, 2024

SUBSCRIBE

Feedback

CIRO SANCTIONS DESJARDINS SECURITIES INC. FOR INADEQUATE SUPERVISION

November 15, 2024

ONTARIO FIRM PAYS $60,000 FOR COMPLIANCE DEFICIENCIES

December 03, 2024

CIRO SANCTIONS FORMER BMO INVESTMENTS REP FROM GUELPH, ON

November 13, 2024

ELEVATE FINANCIAL CORP. AND ITS PRINCIPALS CONSENT TO ASC REGISTRATION SUSPENSION

November 18, 2024